We serve Chemical Name:2-Methylcyclohexyl Acetate CAS:5726-19-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Methylcyclohexyl Acetate
CAS.NO:5726-19-2
Synonyms:EINECS 227-231-1;MFCD00021390;(2-methylcyclohexyl) acetate
Molecular Formula:C9H16O2
Molecular Weight:156.22200
HS Code:2915390090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:191.7ºC at 760 mmHg
Density:0.95 g/cm3
Index of Refraction:
PSA:26.30000
Exact Mass:156.11500
LogP:2.12820
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like EINECS 227-231-1 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2-methylcyclohexyl) acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 227-231-1 Use and application,MFCD00021390 technical grade,usp/ep/jp grade.
Related News: The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. government for hundreds of millions of kits to help regularly screen the country’s population. 2-Methylcyclohexyl Acetate manufacturer Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition. 2-Methylcyclohexyl Acetate supplier The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. government for hundreds of millions of kits to help regularly screen the country’s population. 2-Methylcyclohexyl Acetate vendor Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 2-Methylcyclohexyl Acetate factory Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition.
